PPARG and inflammatory bowel disease: However, AhR inhibition did not prevent the effects of pioglitazone and neither did PPARγ inhibition prevent the effects of FICZ, suggesting that FICZ is still capable of modulating expression of IBD-linked inflammatory surface markers independently of AhR translocation into the nucleus (Figure 4B,C).